Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1. Objectives: To evaluate the response of AID to treatment with the recombinant human IL-1 receptor antagonist anakinra or with the anti-IL-1b.
Maria Cristina Maggio, L.C. (2017). Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 15(S2), 104-104.
Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age
Maria Cristina Maggio;Giovanni Corsello;Umberto Corpora;
2017-01-01
Abstract
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1. Objectives: To evaluate the response of AID to treatment with the recombinant human IL-1 receptor antagonist anakinra or with the anti-IL-1b.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PRES2017_MaggioMC_et_al_P188.pdf
accesso aperto
Descrizione: PRES2017_Anti-IL-1
Tipologia:
Versione Editoriale
Dimensione
66.97 kB
Formato
Adobe PDF
|
66.97 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
